About Vyapitus Specialities
A healthcare organization formed with a single motto - to partner human beings in their quest for healthy living.
Our mission is to witness a healthier and happier world with every passing year. Since 2018, we have built our organization around a strong value system - customer priority, transparency, collaboration, self-control and responsibility - to walk a long, consistent road in the service of patients with chronic and difficult-to-treat diseases.
Our story
A pharmaceutical company by design, not by accident.
Vyapitus Specialities was founded in 2018 with a clear question: what would a pharmaceutical company look like if it only made the medicines a nephrology and transplant practice actually uses? Not a portfolio assembled around what is easy to manufacture or what wins quick share, but a portfolio assembled around the realities of a graft recipient's forty-year journey, a dialysis patient's fortnightly schedule, a CKD outpatient's slow decline.
Eight years on, the answer has taken shape. Five therapy pillars. A short, deliberate list of brands across immunosuppression, CKD management, renal nutrition, hyperuricemia and the gut–kidney axis. Every molecule chosen because it is what a competent nephrology team would reach for, and chosen so that we have the bandwidth to keep that supply unbroken.
We are not the largest company in this space and do not need to be. We do need to be the most dependable one for the patient cohorts we serve.
Vision, mission, objective
What we stand for.
Vision
Vyapitus Specialities aspires to be the most sought-after entity by health specialists and the ailing populace alike - as partners in the management of challenging, chronic and difficult-to-treat diseases.
Mission
To collectively work towards improving the well-being of every strata of society by providing quality therapy and treatment solutions.
Objective
To create a long-term value chain through our business model - positively impacting each associate in our journey of becoming a strong speciality pharmaceutical and allied services organization.
Our values
Customer priority
The patient - and the physician who prescribes for the patient - sits at the centre of every decision we make. Our portfolio, our manufacturing standards and our service model are all built around them.
Sensitivity & long-term commitment
Nephrology is a chronic therapy. It needs sensitivity, continuity and long-term commitment from the people who supply its medicines. A graft recipient or dialysis patient stays on therapy for decades; we plan our supply, our quality, and our relationships against that timescale.
Transparency
In our communication, in our promotional claims, in our dealings with physicians, hospitals, distributors and investors. Nothing on a Vyapitus communication should ever need a footnote we are unwilling to publish.
Collaborative approach
We work alongside nephrologists, transplant surgeons, dieticians, patient organisations and policy stakeholders. The best outcomes in kidney health are never the product of one party.
Self-control
Discipline in scope, in claims, in spending, in growth. A super-specialty company gets its credibility from what it chooses not to do.
Responsibility & eco-sensitivity
To the patient, to the prescriber, to our workforce, to our partners - and to the planet. Sustainable practices in packaging, supply chain and operations are integral to the company we are building.
What we offer
A range of therapeutic solutions across the patient journey.
From finished formulations currently in market to research tools and formulations in our pipeline, we work to assist healthcare specialists in managing challenging, chronic and difficult-to-treat diseases - particularly in the renal and transplant space.
The breadth is deliberately narrow. The depth - in quality, in supply consistency, in clinical service - is where we put our weight.
Our journey
Eight years, one focus.
- 2018
Vyapitus Specialities founded
A focused super-specialty pharmaceutical company built around the management of challenging, chronic and difficult-to-treat diseases.
- 2019
First brand launches
Foundational brands across transplant immunosuppression and CKD management go to market.
- 2021
Renal nutrition portfolio
Ketoanalogue and CKD-specific multivitamin / iron ranges added to the portfolio.
- 2023
Five-year mark, deeper KOL relationships
Sustained growth across leading transplant and nephrology centres; broader CKD-management range.
- 2026
Eight years of Vyapitus
A focused company with a deliberate scope, building for the next decade of kidney care in India.
Quality
The boring work that keeps grafts working.
An organ-transplant patient on tacrolimus does not have the luxury of inconsistency. Our quality posture is built around that reality.
Schedule M (revised) compliant manufacturing
Manufacturing at partner sites certified under India's revised Schedule M (effective 1 January 2025) - aligned with WHO-GMP and PIC/S expectations. CoverGraf® (Tacrolimus) is manufactured in a state-of-the-art facility complying with FDA and WHO-GMP norms.
Stability & batch release
ICH-Q1 aligned stability programmes. Every batch is released against pre-defined release specifications by an authorised person before despatch.
Product safety & oversight
A product-safety setup proportionate to a transplant and CKD portfolio, with established processes for handling any quality or safety concern raised by patients, caregivers or healthcare professionals.